Ind-Swift Laboratories is trading 10.08% up at INR 344.58, as investors continued responding to strong Q1 FY27 results and the August 17, 2026 earnings-call update.
- Operating EBITDA rose 2.85x year over year to INR 33.32 crore.
- Adjusted PAT increased 2.04x year over year to INR 24.68 crore.
- Revenue grew 21.16% year over year, supporting continued buying interest.